Halozyme Therapeutics (HALO) Short-term Investments (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Short-term Investments data on file, last reported at $8.9 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $8.9 million, down 98.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.9 million (down 98.45% YoY), and the FY2025 annual result was $9.0 million, down 98.13% from the prior year.
• Short-term Investments retreated to $8.9 million in Q1 2026 per HALO's latest filing, from $9.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $668.3 million in Q1 2022 and troughed at $8.9 million in Q1 2026.
• A 5-year average of $279.8 million and a median of $217.6 million in 2023 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2024 and 2026: Short-term Investments jumped 168.4% in 2024, then tumbled 98.45% in 2026.
• A 5-year view of Short-term Investments shows it stood at $128.6 million in 2022, then soared by 69.23% to $217.6 million in 2023, then surged by 120.66% to $480.2 million in 2024, then tumbled by 98.13% to $9.0 million in 2025, then decreased by 1.41% to $8.9 million in 2026.
• Business Quant data shows HALO's Short-term Investments at $8.9 million in Q1 2026, $9.0 million in Q4 2025, and $282.3 million in Q3 2025.